NCT02577042View on ClinicalTrials.gov

Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen

PHASE4CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 15, 2015

Primary Completion Date

June 4, 2018

Study Completion Date

June 4, 2018

Conditions
Aging-related Inflammation in HIV-infected Patients
Interventions
DRUG

Raltegravir

Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.

DRUG

PI-based regimen

Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.

DRUG

Atorvastatin

Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks

Trial Locations (1)

08916

Germans Trias i Pujol Hospital, Badalona

All Listed Sponsors
lead

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

OTHER

NCT02577042 - Study of the Effect of Atorvastatin for Reducing Aging-related Complication in HIV-infected Patients Older Than 45 Years Receiving a Protease Inhibitor-based Regimen Versus a Raltegravir-based Regimen | Biotech Hunter | Biotech Hunter